Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Advisors Doubt Benefits Of Low-Dose CT For Lung Cancer Screening

This article was originally published in The Gray Sheet

Executive Summary

A Medicare advisory panel voted “low confidence” on the benefits of low-dose computed tomography for lung cancer screening at an April 30 meeting in Baltimore, Md.

You may also be interested in...



CMS Proposes To Cover CT Lung Cancer Screening, With Lengthy Criteria

CMS proposed Nov. 10 to for the first time cover for lung cancer screening with low dose computed tomography in a decision applauded by imaging and lung cancer groups. The proposed decision memo includes detailed eligibility criteria for coverage including mandatory registry data collection, required patient counseling visits and provider and facility accreditation standards.

Policy Roundup: House FDA Spend Vote Postponed; Congress On Lung Cancer Scans; Remote Monitoring

Health policy news with relevance to the device industry includes a delayed House spending bill and letters on lung-cancer screening and remote patient monitoring.

Burwell Confirmed As HHS Secretary

The Senate approved Sylvia Mathews Burwell as HHS Secretary on a bipartisan vote. The new secretary recently responded to questions on policy issues from the Senate Finance Committee, including on the pending Sunshine Act payment disclosure database and on imaging reimbursement matters.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032961

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel